Tg Therapeutics (TGTX) operates in pharmaceutical preparations within the Biotech Therapeutics theme and trades on NasdaqCM with a market capitalization around $8.57 billion. The company is notable now because quarterly top-line momentum has become a primary driver of the stock while institutional ownership sits at roughly 74% across 547 reporting institutions.
The revenue trend shows a clear sequential expansion: revenue moved from $63.47 million in 2024Q1 to $240.34 million in 2026Q2, roughly a fourfold increase over that span. GAAP diluted EPS has been uneven; there was a large GAAP EPS print of $2.43 in 2025Q3 but more typical GAAP quarterly EPS readings are small positives, including $0.05 in 2026Q2. Selection screens flag continued growth rather than accelerating growth — revenue and EPS are increasing but acceleration metrics are false.
Within the Biotech Therapeutics theme, the company combines growing commercial revenue with strong technical leadership: the stock has outperformed the S&P over both three months (+35% excess return) and 12 months (+56.9% excess return), and institutional sponsorship is high. That mix places the company among theme leaders where execution on continued commercial expansion and margin stability will matter most.
Why now
The timing reflects a transition from development toward commercial revenue proof points, with sequential revenue climbing to $240.3M in 2026Q2 and heavy institutional backing; the stock sits in an established uptrend and has materially outperformed the S&P over recent periods.
The setup
Last close was $55.99 (2026-09-04), just above the 9-day and 50-day moving averages and well above the 200-day line, consistent with a Weinstein Stage 2 continuation trend. RSI is 58.7 and the stock is about 5.2% below its 52-week high, so price action is constructive but the selection framework classifies the name as a watch rather than an actionable fresh-entry setup; 50-day up/down volume ratio is 0.89, indicating recent volume favors down days slightly.
Revenue trajectory
Full-year revenue with year-over-year growth. Solid bars are calendar-year actuals from SEC EDGAR filings (XBRL); dashed bars are analyst consensus via Yahoo Finance (7 analysts), which is published two fiscal years out.Earnings trajectory
Solid bars are quarterly GAAP diluted EPS from SEC EDGAR filings. Dashed bars are analyst consensus, which is typically adjusted (non-GAAP). The two are measured differently, so a step between the last actual and the first estimate usually reflects that change in basis rather than a change in the business.Analyst full-year EPS consensus (typically adjusted): FY'26E $0.95 (-66%) · FY'27E $2.96 (+212%) — 7 analysts
Risks
Three primary risks: GAAP earnings volatility, with a large $2.43 GAAP diluted EPS quarter in 2025Q3 followed by much smaller GAAP results in subsequent quarters; slower-than-expected revenue acceleration, since revenue is rising but acceleration metrics are false; and concentrated institutional ownership—about 74% held by institutions—so coordinated selling or position rotation among large holders could pressure the stock despite current trend strength.
Framework fit
CANSLIM
5/7- CCurrent quarterly GAAP EPS growth ≥ 25%-71%✕
- AAnnual GAAP EPS growth ≥ 25%+1747%✓
- NNew highs — within 15% of 52-week high-5.21%✓
- SSupply/demand — up-day volume leads0.89x✕
- LLeader — outperforming the S&P 500+77% 6m✓
- IInstitutional sponsorshipmodel score 8/10✓
- MMarket in a confirmed uptrendConfirmed uptrend✓
Minervini Trend Template
7/7Stage 2 confirmation checklist: price versus rising long-term moving averages and the 52-week range.
Weinstein Stage
Established uptrend: price is above a rising 30-week proxy, with the 200-day line used as a separate confirmation.